Bloom syndrome is inherited in an autosomal recessive pattern, meaning a child must receive a faulty copy of the BLM gene from both parents to develop the condition. Each parent carries one working copy and one mutated copy, so they typically show no symptoms themselves. When two carriers have a child together, there is a 25% chance the child inherits both mutated copies and is affected, a 50% chance the child is a carrier like the parents, and a 25% chance the child inherits no mutations at all.
What Autosomal Recessive Means
Humans carry two copies of nearly every gene, one inherited from each parent. “Autosomal” means the BLM gene sits on chromosome 15, not on the X or Y sex chromosomes, so the condition affects boys and girls equally. “Recessive” means one working copy of the gene is enough to keep cells functioning normally. Only when both copies are faulty does the disease appear.
This is why Bloom syndrome can seem to appear “out of nowhere” in a family. Two perfectly healthy parents, neither showing any signs of the condition, can each silently carry one mutated copy. Most carrier couples never know their status until an affected child is born.
The BLM Gene and What It Does
The BLM gene, located on the long arm of chromosome 15, provides instructions for making a protein called RecQ helicase. This protein works like a molecular zipper: it unwinds tangled DNA structures so the cell can copy and repair its genetic material accurately.
One of its most important jobs involves managing a process called homologous recombination, a repair system cells use to fix broken DNA strands. After a break is repaired, the two strands of DNA can become intertwined at junctions. The BLM protein dissolves these junctions cleanly, keeping each chromosome’s information intact. Without a functional version of this protein, cells experience far too many swaps of genetic material between paired chromosomes. These excessive exchanges scramble the genome over time, leading to chromosome breaks, rearrangements, and a dramatically elevated risk of cancer at a young age.
A hallmark lab finding in Bloom syndrome is a roughly tenfold increase in sister chromatid exchanges, events where identical chromosome copies swap segments during cell division. This finding is so distinctive that it can be used as a diagnostic marker, even prenatally through chorionic villus sampling.
Types of Mutations
The BLM gene can be disrupted in different ways. Some individuals carry the exact same mutation on both copies of the gene (homozygous), while others carry two different mutations, one on each copy (compound heterozygous). Both scenarios knock out the protein’s function and cause the syndrome.
One specific mutation dominates in people of Ashkenazi Jewish descent. Known as blmAsh, it involves a small but disruptive change at a specific position in the gene: a six-letter deletion paired with a seven-letter insertion. This shifts the reading frame of the gene, making the resulting protein nonfunctional. Nearly all Ashkenazi Jewish individuals with Bloom syndrome are homozygous for this single mutation, a strong signal of a founder effect where one ancestral mutation spread through a relatively small, intermarrying population over many generations.
Carrier Frequency
Bloom syndrome is rare overall, but carrier rates vary sharply by ancestry. In the Ashkenazi Jewish population, approximately 1 in 107 people carries the blmAsh mutation. That translates to a carrier frequency just under 1%. While that sounds small, it means that when two Ashkenazi Jewish individuals have children together, there is a meaningful chance both are carriers.
Because of this relatively high frequency and the near-universal presence of a single identifiable mutation, the blmAsh variant is included in many Ashkenazi Jewish genetic screening panels alongside tests for conditions like Tay-Sachs disease and Gaucher disease. Outside the Ashkenazi Jewish population, carrier rates are much lower and the specific mutations involved are more varied, making population-level screening less straightforward.
What Carriers Should Know
Carriers of one BLM mutation produce enough functional helicase protein from their one working gene copy to maintain normal DNA repair. They do not develop Bloom syndrome and generally have no related health concerns. The risk arises only when two carriers have children together.
For couples who know they are both carriers, each pregnancy carries a 25% chance of producing an affected child. Several reproductive options exist. Preimplantation genetic testing for monogenic disorders (PGT-M) allows embryos created through IVF to be screened for the specific family mutations before being transferred to the uterus. Only embryos that are unaffected, either carrying zero or just one copy of the mutation, are implanted. This approach has a current accuracy rate of around 99% and avoids the need to consider pregnancy termination after a later prenatal diagnosis.
Prenatal diagnosis is also possible through chorionic villus sampling or amniocentesis, where fetal cells are tested either by direct genetic sequencing or by measuring the rate of sister chromatid exchanges in cultured cells. Both approaches can confirm or rule out the diagnosis early in pregnancy.
Why the Inheritance Pattern Matters for Cancer Risk
The autosomal recessive inheritance of Bloom syndrome has a direct biological consequence that sets it apart from many other genetic conditions. Because both copies of the BLM gene are nonfunctional, every cell in an affected person’s body lacks the ability to properly manage DNA repair. This leads to an accumulation of genetic errors from early in development, which is why individuals with Bloom syndrome face a significantly elevated risk of multiple types of cancer, often beginning in childhood or young adulthood. The genomic instability is not limited to one tissue type, so cancers can arise in blood cells, the digestive tract, skin, and other organs.
By contrast, carriers with one working copy maintain enough DNA repair activity to avoid this widespread instability. The difference between one and zero functional copies of BLM is, in practical terms, the difference between normal health and a syndrome defined by fragile chromosomes.